Women of MIA lead the way in melanoma research at SMR
31 October 2018
The Society for Melanoma Research championed women from all sectors of melanoma research at its International Congress in Manchester. Unsurprisingly, Melanoma Institute Australia had a strong contingent of women presenting at SMR, including our Co-Medical Director Professor Georgina Long who, in a double world first, took over as the first female and first Australian President of SMR.
The Congress opened with a keynote presentation from Associate Professor Jennifer Wargo from MD Anderson Cancer Centre in Texas, who spoke on the benefits of teamwork and collaboration in advancing melanoma therapy. During the mid-morning plenary session, Professor Long presented exciting results from the KEYNOTE-029 1B study.
MIA PhD student Tuba Nur Gide presented some pioneering research regarding signatures of response and resistance in patients receiving immunotherapy. Looking at the genes expressed in melanoma samples from MIA patients, she found that genes involving immune memory and activation were higher in responders to immunotherapy, whereas non-responders showed higher levels of genes related to tumour adaptation and survival. While examining the immune cells in the tumours of responders, a specific type of T-cell, was found to be a good predictor of response and survival. The study is one of the first to investigate this in the combination therapy cohort.
Poster presentations from a host of MIA’s finest female minds were also on display throughout the Congress. Dr. Jenny Lee presented her research on the use of circulating tumour DNA (ctDNA) as a predictive marker of relapse and survival. She found that the pre-surgery levels of ctDNA, fragments of DNA from tumour cells that are floating in the bloodstream, could predict survival in Stage III melanoma patients undergoing complete lymph-node dissections.
MIA’s 2018 Medical Oncology Fellow Carina Owen presented on delayed-onset toxicity from anti-PD-1 therapy to highlight the need for clinicians to understand the long-term follow-up requirements of melanoma patients. MIA Biospecimen Bank Manager Valerie Jakrot’s poster presentation detailed the Bank’s role in sample collection, handling, storage and management of neo-adjuvant tissue and blood samples and the associated data.
Dr. Inês da Silva, a clinical researcher working in both medical oncology clinics and the laboratory with Prof Long, had two poster presentations at SMR. In an international collaboration, she developed a model to predict response rate, progression-free survival, overall survival and toxicity for patients on anti-PD-1-based therapies. This model could have a significant impact on clinical care after further study, as it only relied on patient information and a routine blood test. Her second poster presented significant data showing that melanoma patients who develop liver metastases are less responsive to combined immunotherapy with anti-PD-1 and anti-CTLA-4 immunotherapy. She found that liver metastases reduce the activity of the immune system, and recommends further study to possibly unlock these mechanisms and discover new drug targets for these patients.
A ‘STEM for Women' initiative, designed to empower women in melanoma research, was also launched at the SMR Congress. Featuring interviews with Professor Long, Associate Professor Wargo and Valerie Jakrot, among other trailblazing women, it aims to advise, support and inspire women in the scientific community.
In the final plenary session, Professor Georgina Long discussed challenge of resistance to melanoma therapies with a ‘call to action’ for all researchers in the field. Her presentation rounded out a Congress which illuminated and emphasised the ground breaking work of female leaders in the melanoma field.
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina this October, to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
We have been buoyed by the wonderful support for our Melanoma March campaign, and our mission to cover Australia in footprints continues into April!
There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form.
The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.
New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.
Melanoma research saved Bert's life at 101 and now he wants to give back.
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.